AU4561596A - Use of quinoxalines in combination with protease inhibitors as medicaments for treating AIDS and/or HIV infections - Google Patents

Use of quinoxalines in combination with protease inhibitors as medicaments for treating AIDS and/or HIV infections

Info

Publication number
AU4561596A
AU4561596A AU45615/96A AU4561596A AU4561596A AU 4561596 A AU4561596 A AU 4561596A AU 45615/96 A AU45615/96 A AU 45615/96A AU 4561596 A AU4561596 A AU 4561596A AU 4561596 A AU4561596 A AU 4561596A
Authority
AU
Australia
Prior art keywords
quinoxalines
medicaments
combination
protease inhibitors
hiv infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU45615/96A
Other versions
AU710158B2 (en
Inventor
Martin Blunck
Jorg-Peter Kleim
Arnold Paebens
Gunther Rieb
Manfred Rosner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU4561596A publication Critical patent/AU4561596A/en
Application granted granted Critical
Publication of AU710158B2 publication Critical patent/AU710158B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU45615/96A 1995-02-27 1996-02-20 Use of quinoxalines in combination with protease inhibitors as medicaments for treating AIDS and/or HIV infections Ceased AU710158B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19506742 1995-02-27
DE19506742A DE19506742A1 (en) 1995-02-27 1995-02-27 Use of quinoxalines in combination with protease inhibitors as medicaments for the treatment of AIDS and / or HIV infections

Publications (2)

Publication Number Publication Date
AU4561596A true AU4561596A (en) 1996-09-05
AU710158B2 AU710158B2 (en) 1999-09-16

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45615/96A Ceased AU710158B2 (en) 1995-02-27 1996-02-20 Use of quinoxalines in combination with protease inhibitors as medicaments for treating AIDS and/or HIV infections

Country Status (19)

Country Link
EP (1) EP0728481A3 (en)
JP (1) JPH08245392A (en)
KR (1) KR960030951A (en)
CN (1) CN1141196A (en)
AR (1) AR003923A1 (en)
AU (1) AU710158B2 (en)
BR (1) BR9600809A (en)
CA (1) CA2170222A1 (en)
CZ (1) CZ57896A3 (en)
DE (1) DE19506742A1 (en)
FI (1) FI960850A (en)
HR (1) HRP960070A2 (en)
HU (1) HUP9600455A3 (en)
IL (1) IL117247A (en)
NO (1) NO960775L (en)
NZ (1) NZ286058A (en)
PL (1) PL312908A1 (en)
SK (1) SK25196A3 (en)
ZA (1) ZA961516B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (en) * 2000-03-17 2001-09-20 Merck Patent Gmbh Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
JP2016504990A (en) * 2012-12-20 2016-02-18 バイエル ファーマ アクチエンゲゼルシャフト BET protein inhibitory dihydropyridopyrazinone
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164639T3 (en) * 1991-04-15 2002-03-01 Aventis Pharma Gmbh QUINOXALINAS, PROCEDURE FOR PREPARATION AND EMPLOYMENT.

Also Published As

Publication number Publication date
AR003923A1 (en) 1998-09-30
IL117247A0 (en) 1996-06-18
NO960775L (en) 1996-08-28
IL117247A (en) 2000-10-31
CZ57896A3 (en) 1996-09-11
HUP9600455A2 (en) 1996-12-30
AU710158B2 (en) 1999-09-16
CA2170222A1 (en) 1996-08-28
HRP960070A2 (en) 1997-10-31
HUP9600455A3 (en) 1998-04-28
CN1141196A (en) 1997-01-29
KR960030951A (en) 1996-09-17
FI960850A0 (en) 1996-02-23
FI960850A (en) 1996-08-28
DE19506742A1 (en) 1996-08-29
SK25196A3 (en) 1997-05-07
ZA961516B (en) 1996-09-03
PL312908A1 (en) 1996-09-02
BR9600809A (en) 1997-12-23
EP0728481A2 (en) 1996-08-28
HU9600455D0 (en) 1996-04-29
EP0728481A3 (en) 1998-07-08
JPH08245392A (en) 1996-09-24
NO960775D0 (en) 1996-02-26
NZ286058A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
PL311635A1 (en) Hiv protease inhibitors useful in treating aids
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
AU4561596A (en) Use of quinoxalines in combination with protease inhibitors as medicaments for treating AIDS and/or HIV infections
AU2956492A (en) Antibacterial agent and treatment of article therewith
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
ZA98679B (en) Use of quinoxalines in a triple combination with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of aids and/or hiv infections
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU5886796A (en) Peptidyl heterocycles useful in the treatment of thrombin re lateddisorders
AU1556497A (en) Agents for the treatment and prevention of aids
FI935780A (en) HIV protease inhibitors useful in the treatment of AIDS
AU4135493A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
GB9409336D0 (en) Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
AU4812393A (en) Use of rapamycin in the treatment of aids
AU6391994A (en) Compounds active against aids and related infections
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU6251098A (en) Composition for use as a fungistat and for the treatment of fungal infections
AU2811400A (en) Stable formulation containing fumagillin
AU1389897A (en) Use of chemokines for the treatment and prevention of hiv infection
AU2001267177A1 (en) Diagnosis and treatment of herpes infections
AU6627296A (en) Treatment of trichomonal infections with ditiocarb or disulfiram
AU1392601A (en) Prevention and treatment of biomaterial-associated infections

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired